Testosterone, Bone and OsteoporosisTuck S. · Francis R.
aDepartment of Rheumatology, James Cook University Hospital, Middlesbrough, and bSchool of Clinical Medical Sciences, University of Newcastle upon Tyne, Medical School, Newcastle upon Tyne, UK
Do you have an account?
- Rent for 48h to view
- Buy Cloud Access for unlimited viewing via different devices
- Synchronizing in the ReadCube Cloud
- Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00
Osteoporosis and osteoporotic fractures are generally considered to mainly affect older postmenopausal women, but up to 20% of symptomatic vertebral fractures and 30% of hip fractures occur in men. Osteoporotic fractures in men are associated with substantial morbidity, greater excess mortality than in women and account for almost 25% of the cost of osteoporotic fractures in the UK. One of the major secondary causes of osteoporosis in men is hypogonadism, which is found in up to 20% of men with symptomatic vertebral fractures and 50% of elderly men with hip fractures. This chapter outlines the pathogenesis of osteoporosis in men, placing particular emphasis on the importance of sex steroids in the maintenance of bone health. The effects of hypogonadism on the skeleton are described, as well as the consequences of androgen deprivation therapy in men with prostate cancer. Finally, we review the effects of testosterone replacement in hypogonadism and explore other options for the treatment of osteoporosis secondary to loss of sex steroids in men.
Article / Publication Details
Copyright / Drug Dosage / DisclaimerCopyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.